Donate

Publication Details

Need to talk? Call us free*
0800 808 00 00 7 days a week, 8am-8pm
Ibrutinib

Ibrutinib (November 2019)

This factsheet describes the use of ibrutinib for the treatment of certain types of lymphoma (relapsed or refractory mantle cell lymphoma; relapsed or refractory CLL; CLL and a 17p deletion). It covers what ibrutinib is, who can have it and who cannnot, its benefits, how it is given, side effects and precautions while being treated.

Author(s)
Lymphoma Action
Place of publication
Aylesbury
Publisher
Lymphoma Action
Date of publication
November 2019
Pages
9pp
Supplier
https://lymphoma-action.org.uk/
Subject(s)
Lymphomas, Biological therapies, Cancer growth inhibitors, Imbruvica®, Ibrutinib
Format
Factsheet
Language
English
Flesch readability score
51.7
Download this resource
Download this resource
Back to results
Need to talk? Call us free*
0800 808 00 00 7 days a week, 8am-8pm
Donate

About this site

Macmillan sites

Right there with you

We're here to provide physical, financial and emotional support. So whatever cancer throws your way, we're right there with you. Contact us

Follow us

© Macmillan Cancer Support 2019 © Macmillan Cancer Support, registered charity in England and Wales (261017), Scotland (SC039907) and the Isle of Man (604). Also operating in Northern Ireland. A company limited by guarantee, registered in England and Wales company number 2400969. Isle of Man company number 4694F. Registered office: 89 Albert Embankment, London SE1 7UQ. VAT no: 668265007